Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43150
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJoris, S-
dc.contributor.authorDenys, H-
dc.contributor.authorCollignon, J-
dc.contributor.authorRasschaert, M-
dc.contributor.authorde Roodenbeke, DT-
dc.contributor.authorDuhoux, FP-
dc.contributor.authorCanon, JL-
dc.contributor.authorTejpar, S-
dc.contributor.authorMEBIS, Jeroen-
dc.contributor.authorDecoster, L-
dc.contributor.authorAftimos, P-
dc.contributor.authorDe Grève, J-
dc.date.accessioned2024-06-14T08:37:58Z-
dc.date.available2024-06-14T08:37:58Z-
dc.date.issued2023-
dc.date.submitted2024-06-14T08:33:25Z-
dc.identifier.citationESMO Open, 8 (6) (Art N° 102041)-
dc.identifier.urihttp://hdl.handle.net/1942/43150-
dc.description.abstractThe Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR).-
dc.description.sponsorshipThis work was supported by pharmaceutical companies AstraZeneca (global) and Merckx for medication supply and financial contributions. Financial support was provided by Kom op tegen Kanker (Stand up to Cancer), the Flemish Cancer Society (project ID: 1145) and the Stichting Tegen Kanker (no grant number).-
dc.language.isoen-
dc.publisherELSEVIER-
dc.rights2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).-
dc.subject.otheragnostic NGS-
dc.subject.otherolaparib-
dc.subject.othercolorectal cancer-
dc.subject.otherparathyroid cancer-
dc.subject.otherbiliary tract cancer-
dc.subject.otherBRCA1-
dc.subject.otherBRCA2-
dc.subject.otherCHEK2-
dc.subject.otherATM-
dc.titleEfficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study-
dc.typeJournal Contribution-
dc.identifier.issue6-
dc.identifier.volume8-
local.bibliographicCitation.jcatA1-
local.publisher.placeRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr102041-
dc.identifier.doi10.1016/j.esmoop.2023.102041-
dc.identifier.pmid37852034-
dc.identifier.isi001113986700001-
local.provider.typeWeb of Science-
local.uhasselt.internationalno-
item.fullcitationJoris, S; Denys, H; Collignon, J; Rasschaert, M; de Roodenbeke, DT; Duhoux, FP; Canon, JL; Tejpar, S; MEBIS, Jeroen; Decoster, L; Aftimos, P & De Grève, J (2023) Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study. In: ESMO Open, 8 (6) (Art N° 102041).-
item.fulltextWith Fulltext-
item.contributorJoris, S-
item.contributorDenys, H-
item.contributorCollignon, J-
item.contributorRasschaert, M-
item.contributorde Roodenbeke, DT-
item.contributorDuhoux, FP-
item.contributorCanon, JL-
item.contributorTejpar, S-
item.contributorMEBIS, Jeroen-
item.contributorDecoster, L-
item.contributorAftimos, P-
item.contributorDe Grève, J-
item.accessRightsOpen Access-
crisitem.journal.eissn2059-7029-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1.pdfPublished version375.25 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

8
checked on Sep 26, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.